These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 8649795)

  • 21. Effects of immortalization upon the induction of matrix metalloproteinases in rabbit synovial fibroblasts.
    Lin CW; Robbins PD; Georgescu HI; Evans CH
    Exp Cell Res; 1996 Feb; 223(1):117-26. PubMed ID: 8635483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of cellular transformation by glucocorticoid receptor mutants.
    Kameda T; Iba H
    Cancer Res; 1998 Mar; 58(5):867-70. PubMed ID: 9500440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73.
    Smeal T; Binetruy B; Mercola DA; Birrer M; Karin M
    Nature; 1991 Dec; 354(6353):494-6. PubMed ID: 1749429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. cFos is critical for MCF-7 breast cancer cell growth.
    Lu C; Shen Q; DuPré E; Kim H; Hilsenbeck S; Brown PH
    Oncogene; 2005 Sep; 24(43):6516-24. PubMed ID: 16027729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
    Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
    Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
    Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
    Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retinyl methyl ether down-regulates activator protein 1 transcriptional activation in breast cancer cells.
    Agadir A; Shealy YF; Hill DL; Zhang X
    Cancer Res; 1997 Aug; 57(16):3444-50. PubMed ID: 9270011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of the tissue inhibitor of metalloproteinases-1 promoter in culture-activated rat hepatic stellate cells: regulation by activator protein-1 DNA binding proteins.
    Bahr MJ; Vincent KJ; Arthur MJ; Fowler AV; Smart DE; Wright MC; Clark IM; Benyon RC; Iredale JP; Mann DA
    Hepatology; 1999 Mar; 29(3):839-48. PubMed ID: 10051488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies.
    Brown PH; Kim SH; Wise SC; Sabichi AL; Birrer MJ
    Cell Growth Differ; 1996 Aug; 7(8):1013-21. PubMed ID: 8853897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A peptide fragment of ependymin neurotrophic factor uses protein kinase C and the mitogen-activated protein kinase pathway to activate c-Jun N-terminal kinase and a functional AP-1 containing c-Jun and c-Fos proteins in mouse NB2a cells.
    Adams DS; Hasson B; Boyer-Boiteau A; El-Khishin A; Shashoua VE
    J Neurosci Res; 2003 May; 72(3):405-16. PubMed ID: 12692907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of p21WAF1 expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells.
    Lee TH; Chuang LY; Hung WC
    Oncogene; 2000 Aug; 19(33):3766-73. PubMed ID: 10949931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A chicken c-Rel-estrogen receptor chimeric protein shows conditional nuclear localization, DNA binding, transformation and transcriptional activation.
    Zurovec M; Petrenko O; Roll R; Enrietto PJ
    Oncogene; 1998 Jun; 16(24):3133-42. PubMed ID: 9671392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitogenesis of quiescent chick fibroblasts by v-Src: dependence on events at the membrane leading to early changes in AP-1.
    Catling AD; Wyke JA; Frame MC
    Oncogene; 1993 Jul; 8(7):1875-86. PubMed ID: 8510932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site.
    Petz LN; Ziegler YS; Schultz JR; Nardulli AM
    Mol Endocrinol; 2004 Mar; 18(3):521-32. PubMed ID: 14684847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation of a phosphorylation site in the DNA-binding domain is required for redox-independent transactivation of AP1-dependent genes by v-Jun.
    Oehler T; Pintzas A; Stumm S; Darling A; Gillespie D; Angel P
    Oncogene; 1993 May; 8(5):1141-7. PubMed ID: 8479739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cell-specific and selective effect on transactivation by the androgen receptor.
    Gordon DA; Chamberlain NL; Flomerfelt FA; Miesfeld RL
    Exp Cell Res; 1995 Apr; 217(2):368-77. PubMed ID: 7698238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adenovirus type 12 early region 1A expresses a 52R protein repressing the trans-activating activity of transcription factor c-Jun/AP-1.
    Brockmann D; Feng L; Kröner G; Tries B; Esche H
    Virology; 1994 Feb; 198(2):717-23. PubMed ID: 8291251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positive and negative effects of nuclear receptors on transcription activation by AP-1 of the human choline acetyltransferase proximal promoter.
    Schmitt M; Bausero P; Simoni P; Queuche D; Geoffroy V; Marschal C; Kempf J; Quirin-Stricker C
    J Neurosci Res; 1995 Feb; 40(2):152-64. PubMed ID: 7745608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcriptional activities of estrogen and glucocorticoid receptors are functionally integrated at the AP-1 response element.
    Uht RM; Anderson CM; Webb P; Kushner PJ
    Endocrinology; 1997 Jul; 138(7):2900-8. PubMed ID: 9202234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant.
    Rapp UR; Troppmair J; Beck T; Birrer MJ
    Oncogene; 1994 Dec; 9(12):3493-8. PubMed ID: 7970709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.